Your stem-cell service needs an approval file, including its advertising

A MoHFW advisory dated 16 September 2026, announced by PIB on 17 September, asks States and Union Territories that have adopted the Clinical Establishments Act, 2010 to reinforce the existing framework for stem-cell therapy. Routine standard care is limited to Ministry-approved indications; stem-cell use for autism spectrum disorder remains restricted to duly approved clinical trials.

The Ministry asks authorities to circulate the directions to government and private clinical establishments involved in research, treatment, promotion or administration. This is a compliance reminder with direct consequences for how a hospital describes and sells a service.

The underlying judgment predates this week's advisory

The Supreme Court's Yash Charitable Trust judgment of 30 January 2026 rejects offering stem-cell therapy for autism as routine clinical care outside approved and monitored research. It also explains why a patient's willingness to undergo an unproven intervention does not, by itself, resolve the consent problem. Paragraph 151(xiii) identifies professional-misconduct consequences and action under the Clinical Establishments Act's registration and penalty provisions.

The September announcement reiterates that framework. It does not announce a new grace period. The Act-related enforcement route needs to be read with the advisory's jurisdictional scope; it should not be described as a newly commenced, uniform hospital-licensing rule across every state.

Start with what the hospital is offering

The following recommendations are Lifeline's operational analysis. Ask the medical director to assemble a single inventory of stem-cell services offered under the hospital's name. Include visiting-consultant clinics, outsourced units, referral packages and website enquiries. For each indication, identify the responsible clinician, the proposed activity, the documented approval basis and the person who signed off its description.

A generic credential for a consultant or an agreement with a supplier is a poor substitute for an indication-specific file. Have the relevant clinical and regulatory specialists establish what the actual permission covers. Record the institution, site, protocol and scope where research is involved. Management should be able to retrieve the supporting documents without depending on an informal assurance from the unit.

Follow the claim all the way to the patient

Review the service page, brochures, social-media campaigns, enquiry scripts and referral material against that file. Check claims made by partners using the hospital's name. Give marketing a named clinical approver and keep a version history, including the date a disputed statement was corrected. This is an operating control the hospital can put in place without waiting for a new procurement project.

Ask the finance team to explain how the activity is represented in estimates, packages and billing codes. Where staff use a research label, the approval and communication records should support it. Any mismatch should go to the medical director and the institution's legal or research-governance lead before further promotion or new commitments to patients.

Handle existing patients through a clinical transition plan

The January judgment separately addressed patients already receiving interventions and asked the Ministry to work on a transition solution. The material reviewed here does not establish an institution-specific transition protocol. Hospitals should have the treating team and regulatory advisers confirm the applicable position, explain next steps to affected families and preserve continuity records. A management review should not turn into an unplanned interruption of care.

Put the findings into the same accountable process used for hospital licensing and statutory readiness: an identified owner, documentary evidence, unresolved questions and a review date. Our operations and quality services cover the internal audit and responsibility mapping that make such a review usable after the initial meeting.